Dishman teams with Codexis’ for cost saving enzymatic API tech
Codexis’ enzymatic biocatalysis technology offers numerous processing and cost advantages for API and chemical intermediate manufacture says Dishman CRAMS unit president Nick Green.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs